RESUMEN
Glutamate is the main excitatory amino acid, but its presence in the extracellular milieu has deleterious consequences. It may induce excitotoxicity and also compete with cystine for the use of the cystine-glutamate exchanger, blocking glutathione neosynthesis and inducing an oxidative stress-induced cell death. Both mechanisms are critical in the brain where up to 20% of total body oxygen consumption occurs. In normal conditions, the astrocytes ensure that extracellular concentration of glutamate is kept in the micromolar range, thanks to their coexpression of high-affinity glutamate transporters (EAATs) and glutamine synthetase (GS). Their protective function is nevertheless sensitive to situations such as oxidative stress or inflammatory processes. On the other hand, macrophages and microglia do not express EAATs and GS in physiological conditions and are the principal effector cells of brain inflammation. Since the late 1990s, a number of studies have now shown that both microglia and macrophages display inducible EAAT and GS expression, but the precise significance of this still remains poorly understood. Brain macrophages and microglia are sister cells but yet display differences. Both are highly sensitive to their microenvironment and can perform a variety of functions that may oppose each other. However, in the very particular environment of the healthy brain, they are maintained in a repressed state. The aim of this review is to present the current state of knowledge on brain macrophages and microglial cells activation, in order to help clarify their role in the regulation of glutamate under pathological conditions as well as its outcome.
Asunto(s)
Sistema de Transporte de Aminoácidos X-AG/metabolismo , Macrófagos/metabolismo , Microglía/metabolismo , Sistema de Transporte de Aminoácidos X-AG/biosíntesis , Animales , Encéfalo/citología , Encéfalo/enzimología , Encéfalo/metabolismo , Glutamato-Amoníaco Ligasa/biosíntesis , Glutamato-Amoníaco Ligasa/metabolismo , Ácido Glutámico/metabolismo , Humanos , Macrófagos/citología , Macrófagos/enzimología , Microglía/citología , Microglía/enzimologíaRESUMEN
During the 2005-2006 austral summer, an outbreak of fever associated with joint pain hit the Reunion Island inhabitants. Chikungunya virus (CHIKV), the agent involved in this epidemic, was known since 50 years and was thus brought to general attention together with the risk of emergence or re-emergence of arboviral infections. This arbovirus rapidly spread worldwide, specifically in India with millions of cases, but also in Europe through imported cases (>2,000) and fewautochthonous cases in Italy and in France. Human pathology is characterized by arthralgia and myalgia, which persist for months or years. Development of macaque model of CHIKV disease evidenced the key role of monocytesmacrophages in viral persistence.We are reporting herein the present knowledge about physiopathology of the virus and the CHIKV disease. Comparison of animal model data in chronic phase of infection and data acquired in follow-up of patients allows us to propose explanation of mechanisms of inflammation associated with viral infection. This review is aimed at opening discussion about the relationship between the CHIKV, the immune response and the development of virus-induced chronic arthralgia and myalgia.
RESUMEN
HIV associated neurocognitive disorders and their histopathological correlates largely depend on the continuous seeding of the central nervous system with immune activated leukocytes, mainly monocytes/macrophages from the periphery. The blood-brain-barrier plays a critical role in this never stopping neuroinvasion, although it appears unaltered until the late stage of HIV encephalitis. HIV flux that moves toward the brain thus relies on hijacking and exacerbating the physiological mechanisms that govern blood brain barrier crossing rather than barrier disruption. This review will summarize the recent data describing neuroinvasion by HIV with a focus on the molecular mechanisms involved.
Asunto(s)
Complejo SIDA Demencia/inmunología , Complejo SIDA Demencia/patología , Encéfalo/patología , VIH-1/inmunología , VIH-1/patogenicidad , Macrófagos/inmunología , Macrófagos/virología , Encéfalo/virología , HumanosRESUMEN
The human immunodeficiency virus-1 (HIV-1) is a member of the lentivirus genus. The virus does not rely exclusively on the host cell machinery, but also on viral proteins that act as molecular switches during the viral life cycle which play significant functions in viral pathogenesis, notably by modulating cell signaling. The role of HIV-1 proteins (Nef, Tat, Vpr, and gp120) in modulating macrophage signaling has been recently unveiled. Accessory, regulatory, and structural HIV-1 proteins interact with signaling pathways in infected macrophages. In addition, exogenous Nef, Tat, Vpr, and gp120 proteins have been detected in the serum of HIV-1 infected patients. Possibly, these proteins are released by infected/apoptotic cells. Exogenous accessory regulatory HIV-1 proteins are able to enter macrophages and modulate cellular machineries including those that affect viral transcription. Furthermore HIV-1 proteins, e.g., gp120, may exert their effects by interacting with cell surface membrane receptors, especially chemokine co-receptors. By activating the signaling pathways such as NF-kappaB, MAP kinase (MAPK) and JAK/STAT, HIV-1 proteins promote viral replication by stimulating transcription from the long terminal repeat (LTR) in infected macrophages; they are also involved in macrophage-mediated bystander T cell apoptosis. The role of HIV-1 proteins in the modulation of macrophage signaling will be discussed in regard to the formation of viral reservoirs and macrophage-mediated T cell apoptosis during HIV-1 infection.
Asunto(s)
Infecciones por VIH/inmunología , Infecciones por VIH/virología , VIH-1/inmunología , VIH-1/patogenicidad , Activación de Macrófagos , Macrófagos/inmunología , Transducción de Señal , Proteína gp120 de Envoltorio del VIH/inmunología , Proteína gp120 de Envoltorio del VIH/fisiología , Humanos , Factores de Virulencia/inmunología , Factores de Virulencia/fisiología , Productos del Gen nef del Virus de la Inmunodeficiencia Humana/inmunología , Productos del Gen nef del Virus de la Inmunodeficiencia Humana/fisiología , Productos del Gen tat del Virus de la Inmunodeficiencia Humana/inmunología , Productos del Gen tat del Virus de la Inmunodeficiencia Humana/fisiología , Productos del Gen vpr del Virus de la Inmunodeficiencia Humana/inmunología , Productos del Gen vpr del Virus de la Inmunodeficiencia Humana/fisiologíaRESUMEN
The neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4) are key molecules in the central nervous system development, which also exert specific effects on cells of the immune system. With regard to the latter, in vitro as well as in vivo data suggested that neurotrophins may play a role in human immunodeficiency virus (HIV) infection, especially in perivascular spaces where infiltrated macrophages express NGF. In the present study, we examined the expression of neurotrophins and their receptors in human monocyte-derived macrophages (MDMs) during infection by the R5 prototype HIV1/Ba-L strain. We then assessed to what extent neurotrophins themselves modulate infected macrophage survival and the level of virus production. The data show that neurotrophins and neurotrophin receptors are not modulated during HIV replication. Likewise, exogenous neurotrophins, or alternatively the blocking of neurotrophin receptors, neither modulated MDM sensitivity to HIV infection and replication nor altered their viability. In contrast, NGF clearly increased CD184 expression in macrophages, but this did not sensitize them to the X4 isolate HIV-1/Lai infection. Nevertheless, NGF enhanced monocyte chemotactic response to low CXCL-12 concentration regardless of infection. Surprisingly, CXCL-12-attracted monocytes from NGF-stimulated, HIV-infected cultures produced decreased amounts of virus progeny than their non-NGF-stimulated counterparts. This suggests a preferential effect on uninfected monocytes. Together these findings suggest a role for NGF in the continuous attraction of activated monocytes to the perivascular spaces, contributing to the chronic inflammatory state rather than neuroinvasion by HIV.
Asunto(s)
Quimiotaxis de Leucocito , Infecciones por VIH/inmunología , VIH-1/fisiología , Monocitos/inmunología , Factor de Crecimiento Nervioso/fisiología , Quimiocina CXCL12/inmunología , Regulación hacia Abajo , Infecciones por VIH/virología , VIH-1/efectos de los fármacos , Humanos , Monocitos/efectos de los fármacos , Monocitos/virología , Factor de Crecimiento Nervioso/farmacología , Receptores de Factor de Crecimiento Nervioso/metabolismo , Replicación Viral/efectos de los fármacosRESUMEN
The recessive PIEZO2-associated disease, distal arthrogryposis with impaired proprioception and touch (DAIPT), is characterized by hypotonia, perinatal respiratory distress, significantly delayed motor milestones, and progressive symptoms of distal arthrogryposis and scoliosis. Here, we describe the youngest patient with DAIPT to date, who, at the age of 3.5 years, did not show a single clinical sign of distal arthrogryposis or contractures, but had a history of bilateral clubfoot operations. On the contrary, he presented with some features, not described thus far, such as syringohydromyelia, a small cyst of the spinal cord, moderate microcephaly with premature closure of anterior fontanelle, and spontaneous unilateral patella dislocation at the age of 32 months. Using whole exome sequencing, we identified 2 new different loss-of-function mutations in the PIEZO2 gene in our patient. We also review the phenotypes of all 16 previously published patients with DAIPT, summarize the distinctive clinical features of this rare genetic disorder, and recommend that DAIPT be included in the differential diagnosis of floppy infant. PIEZO2 is a unique ion channel that converts mechanical impulses into cellular signals and is involved in various mechanotransduction pathways. In addition to DAIPT, mutations in PIEZO2 have been described to cause 3 more distinct phenotypes of distal arthrogryposis, which are dominant and associated with gain-of-function mutations. On the contrary, recessive DAIPT is associated with loss-of-function PIEZO2 mutations.
RESUMEN
Since 2005, Chikungunya virus (CHIKV) re-emerged and caused numerous outbreaks in the world, and finally, was introduced into the Americas in 2013. The lack of CHIKV-specific therapies has led to the use of non-specific drugs. Chloroquine, which is commonly used to treat febrile illnesses in the tropics, has been shown to inhibit CHIKV replication in vitro. To assess the in vivo effect of chloroquine, two complementary studies were performed: (i) a prophylactic study in a non-human primate model (NHP); and (ii) a curative study "CuraChik", which was performed during the Reunion Island outbreak in 2006 in a human cohort. Clinical, biological, and immunological data were compared between treated and placebo groups. Acute CHIKV infection was exacerbated in NHPs treated with prophylactic administration of chloroquine. These NHPs displayed a higher viremia and slower viral clearance (p < 0.003). Magnitude of viremia was correlated to the type I IFN response (Rho = 0.8, p < 0.001) and severe lymphopenia (Rho = 0.8, p < 0.0001), while treatment led to a delay in both CHIKV-specific cellular and IgM responses (p < 0.02 and p = 0.04, respectively). In humans, chloroquine treatment did not affect viremia or clinical parameters during the acute stage of the disease (D1 to D14), but affected the levels of C-reactive Protein (CRP), IFNα, IL-6, and MCP1 over time (D1 to D16). Importantly, no positive effect could be detected on prevalence of persistent arthralgia at Day 300. Although inhibitory in vitro, chloroquine as a prophylactic treatment in NHPs enhances CHIKV replication and delays cellular and humoral response. In patients, curative chloroquine treatment during the acute phase decreases the levels of key cytokines, and thus may delay adaptive immune responses, as observed in NHPs, without any suppressive effect on peripheral viral load.
Asunto(s)
Fiebre Chikungunya/inmunología , Virus Chikungunya/inmunología , Cloroquina/farmacología , Brotes de Enfermedades , Inmunidad/efectos de los fármacos , Macaca fascicularis/virología , Carga Viral/efectos de los fármacos , Animales , Células Cultivadas , Fiebre Chikungunya/tratamiento farmacológico , Fiebre Chikungunya/epidemiología , Fiebre Chikungunya/virología , Cloroquina/uso terapéutico , Estudios de Cohortes , Modelos Animales de Enfermedad , Fibroblastos/virología , Humanos , Macaca fascicularis/inmunología , Macrófagos/virología , Masculino , Reunión/epidemiología , Replicación Viral/efectos de los fármacosRESUMEN
Neuronal damage in HIV infection results mainly from chronic activation of brain tissue and involves inflammation, oxidative stress, and glutamate-related neurotoxicity. Glutamate toxicity acts via two distinct pathways: an excitotoxic one, in which glutamate receptors are hyperactivated, and an oxidative one, in which cystine uptake is inhibited, resulting in glutathione depletion, oxidative stress, and cell degeneration. A number of studies have shown that astrocytes normally take up glutamate, keeping extracellular glutamate concentration low in the brain and preventing excitotoxicity. They, in turn, provide the trophic amino acid glutamine via their expression of glutamine synthetase. These protective and trophic actions are inhibited in HIV infection, probably as a result of the effects of inflammatory mediators and viral proteins. In vitro and in vivo studies have demonstrated that activated microglia and brain macrophages (AMM) express the transporters and enzymes of the glutamate cycle. This suggests that in addition to their recognized neurotoxic properties in HIV infection, these cells exhibit some neuroprotective properties, which may partly compensate for the inhibited astrocytic function. This hypothesis might explain the discrepancy between microglial activation, which occurs early in the disease, and neuronal apoptosis and neuronal loss, which are late events. In this review, we discuss the possible neuroprotective and neurotrophic roles of AMM and their relationships with inflammation and oxidative stress.
Asunto(s)
Ácido Glutámico/fisiología , Glutamina/fisiología , Infecciones por VIH/prevención & control , Macrófagos/inmunología , Animales , Encéfalo/citología , Encéfalo/inmunología , Ácido Glutámico/farmacología , Glutamina/farmacología , Infecciones por VIH/inmunología , Humanos , Macrófagos/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Modelos Inmunológicos , Relación Estructura-ActividadAsunto(s)
Artritis/patología , Artritis/virología , Biomarcadores , Enfermedades Endémicas , Infecciones por Alphavirus/epidemiología , Infecciones por Alphavirus/inmunología , Infecciones por Alphavirus/patología , Artritis/epidemiología , Artritis/inmunología , Asia/epidemiología , Estudios de Casos y Controles , Fiebre Chikungunya , Citocinas/sangre , Brotes de Enfermedades , Humanos , Estudios LongitudinalesRESUMEN
HIV-1, like the other lentiviruses, has evolved the ability to infect nondividing cells including macrophages. HIV-1 replication in monocytes/macrophages entails peculiar features and differs in many respects from that in CD4 T lymphocytes. HIV-1 exhibits different tropism for CD4 T cells and macrophages. The virus can enter macrophages via several routes. Mitosis is not required for nuclear import of viral DNA or for its integration into the host cell genome. Specific cellular factors are required for HIV-1 transcription in macrophages. The assembly and budding of viral particles in macrophages take place in late endosomal compartments. Viral particles can use the exosome pathway to exit cells. Given their functions in host defence against pathogens and the regulation of the immune response plus their permissivity to HIV-1 infection, monocytes/macrophages exert a dual role in HIV infection. They contribute to the establishment and persistence of HIV-1 infection, and may activate surrounding T cells favouring their infection. Furthermore, monocytes/macrophages act as a Trojan horse to transmit HIV-1 to the central nervous system. They also exhibit antiviral activity and express many molecules that inhibit HIV-1 replication. Activated microglia and macrophages may also exert a neurotrophic and neuroprotective effect on infected brain regulating glutamate metabolism or by secretion of neurotrophins. This review will discuss specific aspects of viral replication in monocytes/macrophages and the role of their interactions with the cellular environment in HIV-1 infection swinging between protection and pathogenesis.
Asunto(s)
Infecciones por VIH/patología , Macrófagos/virología , Enfermedades Virales del Sistema Nervioso Central , VIH-1/patogenicidad , VIH-1/fisiología , Humanos , Replicación ViralRESUMEN
The first Dominique Dormont International Conference on "Viral and host determinantsof HCV, HCMV, and HIV infections "was held in Paris, Val-de-Grâce, on December 3-4, 2004. The following is a summary of the scientific sessions of this meeting (http://www.congres-evenement.fr/ddormont).
Asunto(s)
Infecciones por Citomegalovirus/inmunología , Citomegalovirus/patogenicidad , Infecciones por VIH/inmunología , VIH-1/patogenicidad , Hepacivirus/patogenicidad , Hepatitis C Crónica/inmunología , Enfermedad Crónica , Citomegalovirus/fisiología , Infecciones por Citomegalovirus/fisiopatología , Infecciones por Citomegalovirus/virología , Infecciones por VIH/fisiopatología , Infecciones por VIH/virología , VIH-1/fisiología , Hepacivirus/fisiología , Hepatitis C Crónica/fisiopatología , Hepatitis C Crónica/virología , HumanosRESUMEN
Recent experimental studies showed that activated macrophages/microglia (AMM) express excitatory amino acid transporters (EAATs), suggesting that, in addition to their neurotoxic properties, they also have a neuroprotective role by clearing extracellular glutamate and producing antioxidant glutathione. To test this hypothesis in human, the brain of 12 HIV-positive patients and 3 controls were immunostained for EAAT-1. EAAT-1 was expressed by AMM in all HIV-infected cases but not in HIV-negative controls. Expression varied according to the disease stage. In 5 cases with active HIV-encephalitis (HIVE), AMM strongly expressed EAAT-1 in the white matter and basal ganglia, analogous to HLA-DR and CD68 expression. There was weaker expression in the cortex and perineuronal microglial cells were not involved. In a case with "burnt out" HIVE following highly active antiretroviral therapy (HAART), EAAT-1 expression was mild, identical to that of HLA-DR and CD68 in the white matter and cortex and involved perineuronal microglial cells. In 3 AIDS patients without HIVE and in 3 pre-AIDS cases, EAAT-1 expression in the white matter was weaker than HLA-DR and CD68 expression; there was stronger correlation in the gray matter where perineuronal microglial cells were stained predominantly. Our findings in humans tend to confirm that AMM, particularly perineuronal microglial cells, play a neuroprotective role in the early stages of HIV infection and, possibly, following treatment. This is in keeping with the early microglial activation seen in pre-AIDS cases, and the late occurrence of neuronal loss. It may also explain the reversible cognitive disorders following treatment in some cases.
Asunto(s)
Encéfalo/metabolismo , Transportador 1 de Aminoácidos Excitadores/metabolismo , Infecciones por VIH/metabolismo , Macrófagos/metabolismo , Microglía/metabolismo , Fármacos Neuroprotectores/metabolismo , Complejo SIDA Demencia/metabolismo , Complejo SIDA Demencia/patología , Adulto , Anciano , Biomarcadores , Encéfalo/citología , Encéfalo/patología , Proteína Ácida Fibrilar de la Glía/metabolismo , Infecciones por VIH/patología , Antígenos HLA-DR/metabolismo , Humanos , Masculino , Persona de Mediana EdadRESUMEN
The mechanisms of neuronal apoptosis in prion diseases are unclear. Experimental studies suggest that it may result from 2 associated mechanisms: glutamate-mediated excitotoxicity and oxidative stress. Recent studies showed that activated macrophages/microglia (AMM) express excitatory amino acid transporters (EAATs) in HIV infection, suggesting that they may play a neuroprotective role by clearing extra-cellular glutamate and producing anti-oxidant glutathione. In order to test this hypothesis in prion diseases, samples from cerebral cortex, striatum, thalamus, and cerebellum from 14 patients with Creutzfeldt-Jakob disease (8 sporadic, 2 familial, 2 iatrogenic, and 2 variant), and 4 with fatal familial insomnia (3 homozygous Met/Met at codon 129 of the PRNP gene, 1 heterozygous Met/Val), and 3 controls were immunostained for EAAT-1, GFAP, HLA-DR, CD68, IL-1, caspase 3, and PrP. In prion diseases, EAAT-1 immunopositivity was found in affected areas. Only AMM, interstitial, perivascular, perineuronal (sometimes around apoptotic neurons), or close to reactive astrocytes, expressed EAAT-1. Astrocyte EAAT-1 expression was scarcely detectable in controls and was not detected in prion disease cases. The proportion of AMM expressing EAAT-1 did not correlate with the severity of neuronal apoptosis, spongiosis, astrocytosis, microgliosis, or PrP deposition, but only with disease duration. Occasional EAAT-1 expressing AMM were found in patients with short survival, whereas diffuse EAAT-1 expression by AMM was observed in cases with long survival (24 to 33 months) that most often were heterozygous for Met/Val at codon 129 of the PRNP gene. Our findings suggest that AMM may develop a partial neuroprotective function in long-lasting prion diseases, although it does not seem to efficiently prevent neurological and neuropathological deterioration. Whether this neuroprotective function of microglia is the cause or the effect of longer survival needs to be clarified.
Asunto(s)
Encéfalo/metabolismo , Síndrome de Creutzfeldt-Jakob/metabolismo , Transportador 1 de Aminoácidos Excitadores/metabolismo , Insomnio Familiar Fatal/metabolismo , Macrófagos/metabolismo , Microglía/metabolismo , Adulto , Anciano , Amiloide/genética , Encéfalo/patología , Estudios de Casos y Controles , Niño , Codón , Síndrome de Creutzfeldt-Jakob/genética , Síndrome de Creutzfeldt-Jakob/patología , Femenino , Heterocigoto , Humanos , Insomnio Familiar Fatal/genética , Insomnio Familiar Fatal/patología , Masculino , Metionina , Persona de Mediana Edad , Proteínas Priónicas , Priones , Precursores de Proteínas/genética , Índice de Severidad de la Enfermedad , Factores de Tiempo , ValinaRESUMEN
It is now widely accepted that neuronal damage in HIV infection results mainly from microglial activation and involves apoptosis, oxidative stress and glutamate-mediated neurotoxicity. Glutamate toxicity acts via 2 distinct pathways: an excitotoxic one in which glutamate receptors are hyperactivated, and an oxidative one in which cystine uptake is inhibited, resulting in glutathione depletion and oxidative stress. A number of studies show that astrocytes normally take up glutamate, keeping extracellular glutamate concentration low in the brain and preventing excitotoxicity. This action is inhibited in HIV infection, probably due to the effects of inflammatory mediators and viral proteins. Other in vitro studies as well as in vivo experiments in rodents following mechanical stimulation, show that activated microglia and brain macrophages express high affinity glutamate transporters. These data have been confirmed in chronic inflammation of the brain, particularly in SIV infection, where activated microglia and brain macrophages also express glutamine synthetase. Recent studies in humans with HIV infection show that activated microglia and brain macrophages express the glutamate transporter EAAT-1 and that expression varies according to the disease stage. This suggests that, besides their recognized neurotoxic properties in HIV infection, these cells also have a neuroprotective function, and may partly make up for the inhibited astrocytic function, at least temporarily. This hypothesis might explain the discrepancy between microglial activation which occurs early in the disease, and neuronal apoptosis and neuronal loss which is a late event. In this review article, we discuss the possible neuroprotective and neurotrophic roles of activated microglia and macrophages that may be generated by the expression of high affinity glutamate transporters and glutamine synthetase, 2 major effectors of glial glutamate metabolism, and the implications for HIV-induced neuronal dysfunction, the underlying cause of HIV dementia.
Asunto(s)
Sistema de Transporte de Aminoácidos X-AG/genética , Glutamato-Amoníaco Ligasa/genética , Infecciones por VIH/metabolismo , Macrófagos/metabolismo , Microglía/metabolismo , Simportadores/genética , Complejo SIDA Demencia/fisiopatología , Animales , Encéfalo/metabolismo , Encéfalo/patología , Regulación de la Expresión Génica , Proteínas de Transporte de Glutamato en la Membrana Plasmática , Infecciones por VIH/inmunología , Infecciones por VIH/patología , Humanos , Macrófagos/inmunología , Macrófagos/patología , Ratones , Microglía/inmunología , Microglía/patología , Fármacos Neuroprotectores/metabolismo , RatasRESUMEN
Changes in the fine balance between matrix metalloproteinases and their tissue inhibitors, which drives extracellular matrix turnover, may be critical to central nervous system inflammation in HIV infection as well as in neurotoxicity. Although they do not produce virus when infected by HIV, astrocytes may be directly affected by the virion, because some viral proteins are known to transduce signaling in brain cells and are also sensitive to the major proinflammatory cytokine TNFalpha. We therefore studied the effects of HIV and TNFalpha on MMP-2, MMP-9 and their inhibitors, TIMP-1 and TIMP-2, in astrocytes, by zymography and ELISA, respectively, or by RT-PCR for both of them. HIV slightly increased the production of pro-MMP-2 and pro-MMP-9 by astrocytes, in a dose-dependent manner. TNFalpha strongly induced pro-MMP-9. TIMP-1 and TIMP-2 levels were affected only slightly, if at all, by HIV and TNFalpha. Thus, astrocyte/HIV contact may lead to extracellular matrix activation, which may be strongly amplified by the inflammatory response. Our data strongly suggest that, besides their physiological production of MMP-2, astrocytes would be a major source of MMP-9 in the inflamed brain.
Asunto(s)
Astrocitos/efectos de los fármacos , VIH/fisiología , Metaloproteinasa 2 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/metabolismo , Inhibidor Tisular de Metaloproteinasa-1/metabolismo , Inhibidor Tisular de Metaloproteinasa-2/metabolismo , Factor de Necrosis Tumoral alfa/farmacología , Astrocitos/enzimología , Astrocitos/virología , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Humanos , Metaloproteinasa 2 de la Matriz/genética , Metaloproteinasa 9 de la Matriz/genética , Inhibidores de la Metaloproteinasa de la Matriz , Sistemas Neurosecretores/fisiología , Inhibidor Tisular de Metaloproteinasa-1/genética , Virión/fisiologíaRESUMEN
Microglial cells and macrophages are the only cells within the central nervous system, in which productive HIV infection has been unquestionably demonstrated. Those cells play a key role in the origin of the neuronal dysfunction underlying HIV-related cognitive disorders. The neurotoxicity of the cells is both direct, related to HIV proteins, and indirect, through the release by activated macrophages and microglial cells (AMM) of multiple neurotoxic factors. The mechanisms of neuronal damage, the final irreversible stage of which is neuronal apoptosis, are only partly understood but appear to involve oxidative stress and glutamate-receptor mediated toxicity. On the other hand, recent experimental in vitro and in vivo studies, and neuropathological studies in HIV infected patients at different stages of the disease, tend to show that AMM express excitatory amino acid transporters (EAAT) suggesting that in addition to their neurotoxic properties, they also have a neuroprotective role by clearing extra-cellular glutamate and producing antioxidant glutathione. This neuroprotective role could counteract, at least in the early stages of the disease, the neurotoxicity of AMM explaining the discrepancy between the conspicuous microglial activation at that stage and the absence of cognitive disorder, neuronal loss and neuronal apoptosis. It could also explain the regression of the cognitive disorders in some patients who received highly active antiretroviral treatment.
Asunto(s)
Infecciones por VIH/inmunología , Microglía/inmunología , Animales , Transportador 1 de Aminoácidos Excitadores/fisiología , Transportador 2 de Aminoácidos Excitadores/fisiología , Ácido Glutámico/metabolismo , Humanos , Macrófagos/inmunología , Estrés Oxidativo/fisiología , Receptores de Glutamato/fisiologíaRESUMEN
The kynurenine pathway (KP) and one of its end-products, the excitotoxin quinolinic acid (QUIN), are involved in the pathogenesis of several major neuroinflammatory brain diseases. A relevant animal model to study KP metabolism is now needed to assess whether intervention in this pathway may improve the outcome of such diseases. Humans and macaques share a very similar genetic makeup. In this study, we characterized the KP metabolism in macaque primary macrophages of three different species in comparison to human cells. We found that the KP profiles in simian macrophages were very similar to those in humans when challenged with inflammatory cytokines. Further, we found that macaque macrophages are capable of producing a pathophysiological concentration of QUIN. Our data validate the simian model as a relevant model to study the human cellular KP metabolism in the context of inflammation.
RESUMEN
At the end of 2005, an outbreak of fever associated with joint pain occurred in La Réunion. The causal agent, chikungunya virus (CHIKV), has been known for 50 years and could thus be readily identified. This arbovirus is present worldwide, particularly in India, but also in Europe, with new variants returning to Africa. In humans, it causes a disease characterized by a typical acute infection, sometimes followed by persistent arthralgia and myalgia lasting months or years. Investigations in the La Réunion cohort and studies in a macaque model of chikungunya implicated monocytes-macrophages in viral persistence. In this Review, we consider the relationship between CHIKV and the immune response and discuss predictive factors for chronic arthralgia and myalgia by providing an overview of current knowledge on chikungunya pathogenesis. Comparisons of data from animal models of the acute and chronic phases of infection, and data from clinical series, provide information about the mechanisms of CHIKV infection-associated inflammation, viral persistence in monocytes-macrophages, and their link to chronic signs.
Asunto(s)
Infecciones por Alphavirus/patología , Infecciones por Alphavirus/virología , Artralgia/patología , Artralgia/virología , Virus Chikungunya/inmunología , Virus Chikungunya/patogenicidad , Interacciones Huésped-Patógeno , Infecciones por Alphavirus/inmunología , Animales , Artralgia/inmunología , Fiebre Chikungunya , Modelos Animales de Enfermedad , HumanosRESUMEN
Alzheimer's disease (AD) is the most commonly form of dementia in the elderly. The development of molecules able to detect biomarkers characteristic of AD is critical to its understanding and treatment. However, such molecules must be able to pass blood-brain barrier (BBB) which is a major impediment to the entry of many therapeutic drugs into the brain. Such a limitation applies to the development of magnetic resonance imaging molecular neuroimaging agents using biomarkers of AD-like beta-amyloid deposits, as the common extracellular contrast agents (CAs) are not able to cross an intact BBB. In this work, we have studied the ability of a series of simple Eu(3+) complexes to enter cells overexpressing or not the ABCB1 (P-gp or P-glycoprotein) protein, which is expressed at the BBB and in human embryonic astrocytes. The intracellular uptake of the Eu(3+) complexes of linear and macrocyclic polyaminocarboxylate ligands with different charges and lipophilicities was followed by atomic absorption spectrometry. Based on biochemical argument, we propose that lipophilic contrast agents can be efficiently taken up by cells and accumulate inside mitochondria when they are positively charged. The important point is that they are not P-gp substrates, which is one of the major obstacles for them to cross the BBB.